secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anika Therapeutics, Inc. (ANIK)
CIK:        0000898437
Form:       8-K
Filed at:   2022-05-05T23:59:59+00:00
Accession:  0001171843-22-003332
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anika Q1 revenue $36.7M (+7% YoY); net loss ($2.9M) vs. income; reaffirms FY22 growth
--------------------------------------------------------------------------------

- OA Pain Management revenue $22.7M (+18% YoY); Joint Preservation & Restoration $12.1M (-1%).
- Net loss ($2.9M), ($0.20) per share vs. net income $2.8M ($0.20 diluted) in prior year.
- Adjusted net loss ($1.6M), adjusted gross margin 64% (down YoY) due to supply chain/challenges.
- Cash $90.3M; FY2022 revenue expected toward upper end of low-to-mid single digit growth.
- Appointed Rob Delp as VP U.S. Sales; he previously led Americas for Zimmer Biomet.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/898437/000117184322003332/0001171843-22-003332-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/898437/000117184322003332/f8k_050522.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-003332

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer